Clinical research conductor ICON Plc downplayed impacts from demand softness from the pharmaceutical and biotechnology industries, surprising investors with a $100 million revenue shortfall that led ...

"ICON Public Limited Company (NASDAQ:ICLR): The stock pulled back on news that biotechnology funding has dropped, albeit from very strong growth levels. We continue to believe the company is a ...

Special Counsel Says ICON CEO Steve Cutler says trial activity has been “impacted by cautious spending from biopharma customers in both the biotech and large pharma businesses.” The company ...

Shares tumbled over 10%, leading a chip sell-off as China's new AI model prompted fresh questions on Big Tech's investments.

Bank of America Securities analyst Michael Ryskin reiterated a Buy rating on Icon (ICLR – Research Report) today and set a price target of ...